Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Susan Urba, University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00176800
First received: September 12, 2005
Last updated: July 14, 2014
Last verified: July 2014
  Purpose

Surgery has been the standard of care for esophageal cancer for many years, with limited success. At present, several studies are underway nationwide which utilize chemotherapy combined with radiation therapy prior to the usual surgical regimen. Although this treatment offers some possibility for improvement of patients with esophageal cancer, there remains a significant need for development of new drugs that can substantially impact survival

Investigators at the University of Michigan have been evaluating inhibitors of tumor blood vessel growth (angiogenesis). Specifically, they are evaluating the role of copper in angiogenesis. Copper has been shown to be both a requirement and a potent stimulus for angiogenesis.

Previous studies have shown Tetrathiomolybdate (TM) to rapidly lower copper levels in the blood. The physicians at the University of Michigan are studying whether the addition of TM to the chemoradiation and surgery may increase survival for patients with esophageal cancer.


Condition Intervention Phase
Esophageal Carcinoma
Drug: Tetrathiomolybdate (TM)
Procedure: Radiation
Procedure: Surgery
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pre-Operative Chemoradiation Followed by Post-Operative Tetrathiomolybdate (TM) in Patients With Loco-Regional Esophageal Carcinoma (UMCC 2001-007)

Resource links provided by NLM:


Further study details as provided by University of Michigan Cancer Center:

Primary Outcome Measures:
  • To measure the time to failure (recurrence or progression of disease) in patients with esophageal cancer treated with preoperative chemoradiation, surgery, and post-operative tetrathiomolybdate. [ Time Frame: 8 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To measure the survival time in patients treated with preoperative chemoradiation, surgery, and post-operative tetrathiomolybdate. [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • To measure serum markers associated with tumor angiogenesis pre-operatively, post-operatively, at onset of copper deficiency, at 12 and 24 weeks after copper deficiency, and upon relapse. [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • To measure the microvessel count of the tumor before treatment to determine if there is an association with disease-free survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • To assess the toxicities of this regimen. [ Time Frame: 8 years ] [ Designated as safety issue: Yes ]

Enrollment: 69
Study Start Date: November 2001
Estimated Study Completion Date: November 2015
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
Drug: Tetrathiomolybdate (TM)
Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
Procedure: Radiation
Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
Procedure: Surgery
The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.

Detailed Description:

The pre-study evaluations include a medical history, physical examination, blood laboratory evaluations, and scans to evaluate disease. A CT scan will be performed to measure the size of the subject's tumor(s). The treatment phase of the study includes: 1. Administration of Paclitaxel as an intravenous infusion over 1 hour on Days #1, 8, 15, and 22. 2. Cisplatin will be given as an intravenous infusion after Paclitaxel over 1 hour on Days #1 and 22. 3. Radiation treatments twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.

The subject's esophagus will be surgically removed (esophagectomy) on approximately Day #50.

Approximately four to six weeks after surgery, the subject will start taking Tetrathiomolybdate, one pill a day by mouth, for two years or until treatment is no longer working to control your cancer. The dose may need to be increased by 1 pill every 2 weeks, depending on the results of blood tests that are given on a routine basis to help guide the dosing.

Dietary Restrictions: Subjects may not eat shell fish or liver (organ meat) while on study due to high copper content.

Blood draws (approximately 1-2 tablespoons) will be taken weekly while the subject is undergoing chemotherapy and radiation prior to surgery. Prior to your surgery a CT scan will also be administered. Four to six weeks after surgery (when the subject is starting to take Tetrathiomolybdate), a blood test (approximately 1 teaspoon) will be performed every other week for 2 times, and monthly thereafter. This blood test will check for the amount of copper in the subject's blood. When the level of copper has been lowered sufficiently (which will be determined by your physician) an additional blood test and a baseline chest x-ray will be obtained.

Additional blood will be drawn (approximately 1-2 tablespoons) and tested every 6 months for the first 2 years.

There are circumstances under which treatment may be discontinued whether the subject agrees or not. These circumstances include: the subject's tumor gets worse despite the treatment; side effects of the treatment are too dangerous for the subject; new information about the drug becomes available and this information suggests the drug will be ineffective or unsafe for the subject.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Eligibility Requirements

  1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction
  2. No prior treatment for the esophageal cancer allowed.
  3. No prior thoracic or upper abdominal radiation.
  4. Disease should be limited to the esophagus and regional lymph nodes. Regional lymph nodes are described in Section 4.0. However, celiac node enlargement will be acceptable for tumors of the distal esophagus, because they will be included in the radiation field.
  5. Disease must be able to be encompassed in a single radiation field.
  6. No medical contraindication to surgery
  7. All treatment is to be administered at the University of Michigan Medical Center.
  8. Karnofsky Performance Status > 70 %.
  9. Age range: 18 - 75 years old.
  10. Adequate baseline hematopoetic function:

    Platelet count equal to or greater than 100,000/mm3 Absolute granulocyte count equal to or greater than 1500/mm3 Hematocrit equal to or greater than 29% (patients may be transfused to this level)

  11. Adequate baseline organ function :

    Creatinine clearance >/= 60 mls/min Bilirubin equal to or less than 1.5 x upper limits of normal AST/ALT equal to or less than 2.5 x upper limits of normal

  12. Patients with any complaint of hearing loss should be evaluated with an audiogram. The average pure tone average hearing loss from 500-2000Hz should not exceed 30 dB. If it does, the patient should be warned that further hearing loss may be very noticeable and permanent.
  13. Prior malignancy is acceptable if the patient is considered to be cured. In most cases this will mean a 5-year disease-free period. Contact the Principal Investigator for any specific question regarding this requirement.
  14. Patients with active infection, serious inter-current medical conditions are ineligible, according to the judgment of the investigators.
  15. Pregnant or lactating females are not eligible. Women of childbearing Potential must be using contraception throughout the entire period of treatment.
  16. Ability to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00176800

Locations
United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Cancer Center
Investigators
Principal Investigator: Susan Urba, M.D. University of Michigan Cancer Center
  More Information

No publications provided

Responsible Party: Susan Urba, Principal Investigator, University of Michigan Cancer Center
ClinicalTrials.gov Identifier: NCT00176800     History of Changes
Other Study ID Numbers: UMCC 2001-007, HUM 49005 Legacy 2001-0623
Study First Received: September 12, 2005
Last Updated: July 14, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Tetrathiomolybdate
Molybdenum
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses
Trace Elements
Micronutrients

ClinicalTrials.gov processed this record on August 27, 2014